RIZ1 displays strong tumor suppressive activities, and loss-of-function mutation or deletion, and altered DNA methylation of RIZ1 have been associated with the progression of various cancers, such as ovarian carcinoma, lymphomas, colorectal cancer and glioma (8–11). Here, PRDM2 is linked to lymphoma.